AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports reut.rs/4x9zreO

How each outlet headlined it

• Reuters

  AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports reut.rs/4x9zreO
• STAT News center

  AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of ​the world's biggest drugmakers
• Bloomberg center

  AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. (Source: Bloomberg)